Every CFO in self-funded benefits has had the same experience. A new pharmacy report lands on the desk. The math is cleaner than last year. The rebate line is larger. The PBM model is more legible. And total drug spend is still climbing.
Transparency is not the same thing as control. The pharmacy benefits industry spent the better part of a decade building the case for pricing reform, and that case is legitimate. A recent market report from RxBenefits documents the shift in detail: the Consolidated Appropriations Act of 2026 now mandates 100% rebate pass-through and stricter fiduciary standards for plan sponsors. Spread pricing is being phased out. The three major PBMs are each rolling out versions of pass-through and cost-plus models. For the first time, CFOs can see what they are actually paying at the drug level.
But visibility into a problem is not the same as solving it.
The report notes that specialty drugs now account for more than half of total pharmacy spending, concentrated in roughly 2% of a plan’s membership. GLP-1 prescriptions for weight loss, a category most benefit designs were never built to absorb, are compounding the pressure in ways that no pricing model reform directly addresses. When the cost driver is clinical volume rather than pricing opacity, a cleaner invoice does not change the underlying number.
This is the gap the transparency conversation consistently skips.
The Most Expensive Prescription Is the One That Should Not Have Been Written
The most expensive prescription in any pharmacy benefit is not the one with the highest list price. It is the one that should not have been written at all, or that could have been replaced by a clinically equivalent alternative at a fraction of the cost. Polypharmacy, unnecessary refills, missed deprescribing opportunities, and brand prescriptions where biosimilars are available represent a category of spend that no rebate pass-through model touches. These decisions happen upstream, at the point of prescribing, and they are made by physicians who often lack complete visibility into a patient’s full medication profile.
Redirecting that decision point is where durable savings actually live.
Physician Direction Is the Missing Layer
Physician-directed pharmacy optimization operates inside the existing clinical workflow rather than around it. When prescribers receive complete medication data for their patients, along with evidence-based recommendations for therapeutic alternatives, they engage. The savings compound across deprescribing, biosimilar adoption, and therapeutic switching, categories where the clinical and financial case is already established and where physician trust determines whether the opportunity is captured or lost.
The $300 million in drug spend reduction RazorMetrics has delivered for clients did not come from a new pricing model. It came from giving physicians the information and the prompt to make better prescribing decisions on behalf of their patients.
Proof Over Promises
Pricing transparency is a necessary foundation. It is not a savings strategy. CFOs who treat model reform as the endpoint will find themselves with a more legible bill and the same trajectory. The plans that bend the cost curve are the ones that address what transparency cannot reach: the clinical decisions that determine what gets prescribed in the first place.
RazorMetrics builds physician-directed pharmacy optimization into the existing prescriber workflow, with no new apps, no member disruption, and a guaranteed 2x ROI in year one.
